Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054659 · ClinicalTrials.gov registry record · NA
CGM and DFU Healing Post-discharge
A NA study of Diabetic Foot and Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown, sponsored by Emory University.
- Active
- Registry status
- NA
- Development phase
- 116
- Enrollment target
- 2
- Study locations
NCT06054659: Active NA study of Diabetic Foot and Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown, sponsored by Emory University.
NCT06054659 is a NA study of Diabetic Foot and Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown that is active but no longer recruiting, run by Emory University. The registered enrollment target is 116 participants, below the 10,337-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054659, a NA study of Diabetic Foot and Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to look at the benefits of using a Continuous Glucose Monitoring (CGM) system compared with standard-of-care testing for patients with type 2 diabetes and diabetic foot ulcers (DFU) and how this will improve wound healing. The CGM system allows medical staff and patients with diabetes to monitor and make treatment decisions to improve glucose control, without the need for performing fingersticks. Hence, the use of CGM will decrease the painful and burdensome task of performing finger sticks several times per day and may prevent low blood glucose in patients with diabetes.
Primary Outcome
Number of participants with DFU wound healing rates in both groups
Conditions Studied
Interventions
- BEHAVIORAL Diabetes Education
- DEVICE Real Time Continuous Glucose Monitoring (rt-CGM)
- OTHER Fingerstick blood glucose (FBG) monitoring
Study Locations (2)
Georgia
- Grady Health System - Atlanta
- Emory Decatur Hospital - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-02 |
| Phase | NA |
What the registry record for NCT06054659 still lists
NCT06054659 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 10,337-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetic Foot appearing as the primary indexed condition, and to 3 interventions - of which Diabetes Education is the first listed.
NCT06054659 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06054659 about?
NCT06054659 is a clinical study titled "CGM and DFU Healing Post-discharge". The purpose of this study is to look at the benefits of using a Continuous Glucose Monitoring (CGM) system compared with standard-of-care testing for patients with type 2 diabetes and diabetic foot ulcers (DFU) and how this will improve wound healing. The CGM system allows medical staff and patient...
What is the current status of trial NCT06054659?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 116 participants. The study started on 2024-02-20. Estimated completion is 2026-02.
What conditions does trial NCT06054659 study?
This clinical trial studies the following conditions: Diabetic Foot, Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown.
What interventions are being tested in trial NCT06054659?
The interventions under investigation include: Diabetes Education (BEHAVIORAL), Real Time Continuous Glucose Monitoring (rt-CGM) (DEVICE), Fingerstick blood glucose (FBG) monitoring (OTHER).
Who is sponsoring clinical trial NCT06054659?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054659 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06054659's enrollment target sits among peer trials
116 17th of 30 higher than 13 of 30 other Diabetic Foot trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Effectiveness of Remote Foot Temperature Monitoring
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care Versus Standard of Care
RECRUITING · NA
-
Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers
RECRUITING · NA
-
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI